|
|
Profile
|
Delegates :
Tamio Mizukami, Ph.D. |
|
Incorporated :
April 3 , 2006 |
Paid in Capital :
92 Million yen |
Employees :
6 人 |
Address :
Tamura-cho 1281-8 Nagahama Bioincubation Center, Nagahama-si SHIGA
〒526-0829
|
TEL/FAX :
/ |
URL：
https://www.frontierpharma.net/english-home/ |
Attachment :
|
Mission/Background :
Vision
・In order to contribute to cell medicine and drug discovery in the world, we will evolve our our cell visualization technology into the essential technology of cell manufacturing/quality control and drug discovery using stem cells.
・We will continue to pioneer the frontier of digital cell measurement with our cell visualization technology.
Mission
・We provide solutions using cell visualization technology after accurately grasping the on-site needs and issues of cell medicine and drug discovery researchers and engineers of our customers' pharmaceutical companies.
・ By eliminating bottlenecks in cell manufacturing/quality control and drug discovery processes, we contribute to system efficiency and reduction of manufacturing manufacturing and R&D costs. |
|
Technology & Business
|
Frontier Pharma's “Cell Visualization Technology” provides a solution for value creation/efficiency in R&D through digitalization, responding to the needs and challenges in the field of cell medicine and drug discovery.
Through the development of numerous applications that can be used in drug discovery and pharmaceutical manufacturing, we have accumulated a wide range of AI technologies and experience, including highly accurate image generation and classification.
(Cell Production and Quality Control)
(1) Non-invasive cell monitoring enables cell manufacturing and quality control processes to be more sophisticated, efficient, and labor-saving.
(2) Examples of application:
- Non-invasive measurement of cell number, density, morphological characteristics (1-cell area, perimeter, etc.), and quality (survival rate, senescence rate, etc.) of cell manufacturing in-process
- Expert alteration: AI evaluation of cell quality reflecting expert's evaluation index
|
|
Products & Service
|
Products & Service Name
|
Stage
|
Outline
|
Milestone
|
Automated system for measuring proliferation parameters and evaluating the quality of mesenchymal stem cells (MSCs)
|
Launched
|
|
|
Automated system for measuring iPS cell proliferation parameters and evaluating quality
|
Launched
|
|
|
Next-generation standard quality assessment technology for iPS cells by visualizing mitochondrial function
|
Discovery
|
|
|
Phenotypic assay technology targeting organelle dysfunction such as mitochondrial disease
|
Discovery
|
|
|
Real-time, non-destructive evaluation technology for organoids and spheroids
|
Preclinical
|
|
We aim to apply this technology to drug discovery screening and pharmacological and toxicity evaluation.
|
|
Highlights
|
・Patents have been granted in Japan, the United States, Europe and China for AI technology that can determine the position of specific cell parts, which is the basis of "cell visualization technology" (Japanese patent 6627069; US patent 11734824; European patent 3805401; ZL 2019800316607).
・Our next-generation standard quality assessment technology for iPS cells by visualizing mitochondrial function has been selected for the Ministry of Economy, Trade and Industry's Go-Tech project for 2024.
|
|
Alliance strategy
|
・We would like to see this next-generation standard quality assessment technology for iPS cells by visualizing mitochondrial function widely used by researchers and companies engaged in the development of regenerative medicine products using iPS cells. We would appreciate it if you could contact us.
|
|
|